Jasper Therapeutics
Blood & Organ Banks · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2200 Bridge Pkwy Ste 102, Redwood City, ...Phone Number
(650) 549-1400Website
www.jaspertx.comRevenue
-Stock Symbol
JSPRIndustry
About Jasper Therapeutics
Jasper Therapeutics is focused on developing innovative therapies for significant immune-mediated diseases through a pipeline of antibody therapeutics. Their lead candidates include Vensobafusp alfa (KP104), an investigational bifunctional biologic for rare renal disorders, and briquilimab, an anti-KIT antibody for mast cell disorders. The company collaborates with biotech veterans and leading academic institutions across the United States, Europe, and China to enhance disease outcomes. Their target clients include patients suffering from chronic immune disorders, with a commitment to advancing clinical development for their investigational agents.Explore more
Jasper Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Jasper Therapeutics
Compare insights from companies similar to Jasper Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Jasper Therapeutics Tech Stack
A closer look at the technologies used by Jasper Therapeutics
See more technologies
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jasper Therapeutics
Sign Up For FreeTo access detailed company insights
Jasper Therapeutics is focused on developing innovative therapies for significant immune-mediated diseases through a pipeline of antibody therapeutics. Their lead candidates include Vensobafusp alfa (KP104), an investigational bifunctional biologic for rare renal disorders, and briquilimab, an anti-KIT antibody for mast cell disorders. The company... Read More
